Srivandana Akshintala

Cancer Institute (WIA) — India

Medicine · Health Sciences

18h-index1.0kcitations138works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(51), PI3K/AKT/mTOR signaling in cancer(42), Chronic Myeloid Leukemia Treatments(42), Thyroid Cancer Diagnosis and Treatment(31), Neurofibromatosis and Schwannoma Cases(20)

Publications136 total

The prostate is a common site of disease in patients with MEN2B and medullary thyroid carcinoma
Endocrine Related Cancer·2025Open Access
Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Figure S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Table S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Table S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Table S3 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Appendix S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Figure S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Table S4 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Identifying caregiver-reported modifiable barriers to pediatric oncology clinical trial enrollment and participation
2025Open Access
Identifying caregiver-reported modifiable barriers to pediatric oncology clinical trial enrollment and participation
2025Open Access
Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1- or SMARCA4-deficient tumors: PEPN2121.
Journal of Clinical Oncology·2025
Phase II study of axitinib in patients with <i>NF2</i>-related schwannomatosis and progressive vestibular schwannomas
Neuro-Oncology Advances·2025Open Access
Tumor Volume Doubling Time of Less Than 1 Year Is Associated With a Higher Risk of Death From Medullary Thyroid Cancer
The Journal of Clinical Endocrinology & Metabolism·2024· 1 citedOpen Access
Supplementary Figure S2 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
2024Open Access
Supplementary Table S2 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
2024Open Access
Supplementary Figure S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
2024Open Access
Supplementary Appendix S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
2024Open Access
Supplementary Table S1 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
2024Open Access
page 1 of 7Next →

Frequent Co-authors

Brigitte C. Widemann(39), Eva Dombi(33), John Glod(29), Seth M. Steinberg(24), Andrea M. Gross(20), Haiyan Lei(19), Jack F. Shern(19), Marielle E. Yohe(16), Donna Bernstein(15), Rosandra N. Kaplan(15), Joanne Derdak(15), Isabel Palacio-Yance(15), Kailey R. Herrera(15), Lee J. Helman(15), Leo Mascarenhas(15), Fariba Navid(15), Christine M. Heske(15), R. Taylor Sundby(14), Markku Miettinen(14), Helen X. Chen(14)